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 Introduction 
 Discovery of Th 17 cells 
 Until about a decade ago, many human autoimmune diseases 
and the corresponding experimental animal models had been 
viewed as being driven by Th 1 cells. However, immunologists 
encountered a dilemma when they realized that experimental 
autoimmune encephalomyelitis (EAE: a mouse model of multiple 
sclerosis) and collagen-induced arthritis (CIA: a mouse model 
of rheumatoid arthritis) both were aggravated by the absence 
of Th 1 associated cytokines, receptors or transcription factors, 
such as IFN-γ, IFN-γ receptor, IL-12 p35, IL-12 receptor  2, or 
Stat1. 1–5 However, mice lacking the IL-12p40 subunit, which is 
found not only in IL-12 but also in IL-23, were resistant to these 
diseases, and IL-23p19 knockout mice were shown to be protected 
from EAE 6 and CIA. 7 Th is paradox was resolved in 2005 by a 
discovery of new subset of CD4+ T cells that produce IL-17A and 
IL-17F, expand in response to IL-23, and induce EAE and CIA 
upon adoptive transfer in mice. 8–10 Th ese lymphocytes, termed 
Th 17 cells, are characterized by expression of RORγt as a master 
regulator gene as well as secretion of IL-17A, IL-17F, IL-21, and 
IL-22. Th 17 cells are crucial in host defense against extracellular 
bacteria and some fungi, which Th 1 and Th 2 immunity are 
not fully eff ective against, and also play essential roles in many 
autoimmune or infl ammatory diseases, both in mice and humans 
( Table 1 ). 11–13 
 Discussion 
 What is the connection between Th 17 cells and rheumatoid 
arthritis? 
 Multiple lines of evidence indicate that Th 17 cells are important 
in rheumatoid arthritis (RA). As summarized in  Table 2 , IL-
17 activates a diverse array of cell types that participate in the 
pathogenesis of RA, including synovial fi broblasts, monocytes, 
macrophages, chondrocytes, and osteoblasts. IL-17 induces 
production of proinfl ammatory cytokines, such as TNF, IL-1, 
IL-6, IL-23, which amplify positive feedback loops that commit 
naïve CD4 T cells to the Th 17 lineage. 14–16 By inducing chemokine 
production, IL-17 indirectly attracts numerous eff ector T cells, 
B cells, monocytes, and neutrophils to the infl amed joint. 17 Of 
note, acting in synergy with TNF and IL-1-β, IL-17 induces 
CCL20, 18 which strongly attracts lymphocytes, including Th 17 
cells that express CCR6, a receptor for CCL20. In bone, IL-17 
stimulates osteoblasts to express receptor activator of nuclear 
factor kappa-B ligand (RANKL). 19 Such osteoblasts then activate 
osteoclasts that express RANK as a membrane receptor. Th is 
interaction leads to bone resorption. Finally, induction of 
matrix metalloproteinases (MMPs) 20 and vascular endothelial 
growth factor (VEGF) 21 are crucial in tissue destruction and 
angiogenesis, respectively. 
 Brief overview of Th 17 diff erentiation in mice 
 In mice, the combination of TGF-β and IL-6 or IL-21 induces 
Th 17 cells. 22–24 IL-6 or IL-21 phosphorylates Stat3, which induces 
RORγt expression. 25 Stat3 and RORγt appear to cooperate with 
each other 26 and bind to the IL-17 promoter to induce IL-17 
expression. 27,28 TGF-β induces not only RORγt but also FoxP3 
(master regulator gene of regulatory T cells: Tregs), 23,29,30 which 
physically associates with RORγt as well as Runx1. 28,29 In the 
absence of proinfl ammatory cytokines, FoxP3, through interaction 
with Runx1, inhibits RORγt-directed IL-17 expression, which 
is crucial in maintaining homeostasis of the immune network 
through generation of Tregs. 28,29 However, in the presence of 
proinfl ammatory cytokines, Stat3 and IRF4 both play essential 
roles in IL-6/21- and IL-6-mediated down-regulation of FoxP3, 
respectively, 31,32 aft er which RORγt primarily cooperates with 
Runx1 to induce IL-17. 28 In this manner, IL-6 or IL-21 play a pivotal 
role in tipping the balance toward Th 17, but not Treg diff erentiation 
by inhibiting TGF-β−mediated FoxP3 expression. 23,29 
 IL-21 produced by Th 17 cells in the presence of TGF-β 
induces Th 17 cells, creating an autoamplifi cation loop for Th 17 
diff erentiation. 26,33,34 Th us, IL-21 might play a crucial role in 
maintaining a precursor pool of Th 17 cells when the supply of 
IL-6 is limited. 
 Both IL-6 and IL-21, in cooperation with TGF-β, induce 
expression of the IL-23 receptor in a Stat3- 26 and RORγt-dependent 33 
fashion. Stat4, which has been viewed to be primarily essential for 
IL-12 signaling for Th 1 lineage commitment, was shown to also 
be important for IL-23-mediated expression of IL-17 in CD4 T 
cells  in vitro. 35 
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 How does TGF-β contribute to human Th 17 diff erentiation? 
 In humans, TGF-β induces ROR-c (human homolog of RORγt), 
which is essential for IL-17 expression. 36,37 However, high 
TGF-β suppresses ROR-c directed IL-17 expression, which is 
relieved either by IL-1, IL-6, or 21. 36 Th us, the basic molecular 
mechanism is probably conserved between the two species. 
Analogous to mice, it is plausible that TGF-β possesses a dual 
potential; induction of either Tregs or Th 17 cells, depending 
on its concentration and on the cytokine milieu. Targeted 
administration of TGF-β in conjunction with neutralization 
of IL-1/IL-6/IL-23 might theoretically represent an eff ective 
maintenance therapy for Th 17 driven autoimmune diseases 
including RA, provided that the disease is in remission. Dendritic 
cells (DCs) genetically engineered to express immunoregulatory 
cytokines are a potential approach to targeting T cells, and 
their use in infl ammatory arthritis has been explored in mouse 
systems. 38,39 
 What are the roles for proinfl ammatory cytokines (IL-1, IL-6, 
IL-21, IL-23) in human Th 17 diff erentiation? 
 In humans, the combination of TGF-β and IL-6 does not induce Th 17 
cells. Although TGF-β was defi nitively shown to be indispensable, 
it has been controversial as to what proinfl ammatory cytokines in 
combination with TGF-β are necessary and suffi  cient to induce 
human Th 17 cells. Manel reported that TGF-β + IL-1 + IL-6 or 
IL-21 or IL-23 was necessary and suffi  cient for human Th 17 cell 
diff erentiation. 36 Yang and Volpe found TGF-β + IL-21 or TGF-β + 
IL-1 + IL-6 + IL-23 to be Th 17 inducing cytokine combinations. 37,40 
We will discuss potential roles of each proinfl ammatory cytokine 
in human Th 17 diff erentiation below. 
 IL-1 
 Unlike IL-6, IL-1 is not absolutely indispensable for Th17 
diff erentiation in mice; however, defi ciency of IL-1 signaling 
significantly impairs Th17 differentiation both  in vivo and 
 in vitro. 41 Furthermore, lack of IL-1 signaling delays the onset and 
reduces the incidence and severity of EAE. 41 At a low concentration 
of TGF-β , IL-1 synergizes with IL-6 + IL-23 to induce Th 17 cells 
without down-regulating FoxP3. 41 IL-1 signaling is essential for 
expression of RORγt and IRF-4, whereas over-expression of RORγt 
and IRF-4 restores IL-17 expression independent of IL-1. 41 
 Given such significant contributions of IL-1 to Th17 
diff erentiation in mice, it would be surprising if IL-1 were not 
involved in development of human Th 17 cells. Expression of the 
IL-1 receptor in naïve and memory CD4 T cells from peripheral 
blood is associated with higher expression of IL-17, ROR-c, 
IRF4, and IL-23 receptor, even before T cell receptor triggering. 42 
Whereas it is not entirely clear how IL-1 promotes human Th 17 
diff erentiation, IL-1 appears to synergize either with IL-6, IL-21, 
or IL-23 to induce Th 17 cells in the presence of TGF-β. 36 Th is is 
consistent with what was defi ned in mice, that the IL-1 receptor is 
induced by IL-6 and is dependent on Stat3 and RORγt expression. 41 
How the signaling cascade triggered by the IL-1R is involved in 
human Th 17 diff erentiation remains to be investigated. 
 In clinical practice, the IL-1 receptor antagonist: anakinra, has 
been used to treat RA. Several RCTs and metaanalyses indicated 
that treatment with anakinra in patients with RA refractory to 
methotrexate not only improved the clinical outcomes, including 
ACR 20, 50, and 70 responses and functional status, but also 
delayed the radiographic progression. 43–46 However, the potency 
of anakinra in RA is typically inferior to other biologics such 
as TNF antagonists. 43 In general, anakinra is well tolerated. A 
study involving 1,399 patients revealed a slightly higher incidence 
of serious infections in anakinra group, none of which were 
attributed to opportunistic organisms or resulted in death. 47 
Th e risk of infections correlates with either concomitant use of 
steroid 48 or a higher dose (>100mg/day) of anakinra. 49 
 IL-6 
 In humans, the role for IL-6 in Th 17 diff erentiation has not been as 
rigorously studied as in mice. Whereas IL-6 + TGF-β with/without 
IL-23 do not induce human Th 17 cells, IL-6 appears to synergize 
with IL-1 in the presence of TGF-β. 36 Although Yang indicated 
that the combination of IL-6 + TGF-β induced 
a level of ROR-c comparable to the eff ect of 
IL-21 + TGF-β, only the latter combination 
induced Th 17 cells. 40 Volpe demonstrated that 
lack of IL-6 did not completely abrogate, but 
substantially impaired, Th 17 diff erentiation. 37 
In view of these confl icting data, whether IL-6 
is absolutely indispensable for human Th 17 
diff erentiation awaits further investigations. 
 Th e effi  cacy and safety of an anti-IL-6 
receptor monoclonal antibody (tocilizumab) 
have been proven in RA. Several RCTs 
indicated that tocilizumab is effective in 
patients with RA refractory to conventional 
DMARDs or TNF antagonists, with greater 
effi  cacy at higher doses. 50 One of these studies 
showed that tocilizumab in combination 
with methotrexate reduced markers of 
systemic bone resorption as well as cartilage 
turnover. 51 
Strong evidence: Moderate evidence: 
 Multiple sclerosis  Periodontal disease
 Rheumatoid arthritis  Loosening of prosthetic joint
 Psoriasis  Chronic GVHD
 Infl ammatory bowel disease  Allograft rejection
 Steroid resistant asthma  SLE
Table 1.  Human autoimmune or infl ammatory diseases in which contributions of 
Th17 cells have been suggested. 
Target cell Mediators produced Major functions
Synovial fi broblasts IL-6, IL-1

, IL-23




































Adapted from Lundy SK et al. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Res Ther. 
2007; 9(1)202
 Table 2.  Effects of IL-17 on cells of the joint. 
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 IL-21 
 As noted above, IL-21 might be an autoamplifi cation factor for 
Th 17 cells in mice. Moreover, the IL-21 receptor Fc fusion protein 
was shown to improve clinical and histologic signs of CIA. 52 
 In humans, the combination of TGF-β + IL-21 induced 
Th 17 cells  in vitro. 40 Although the mechanism of how IL-21 
is involved in human Th 17 diff erentiation is unclear, IL-21 appears 
to synergize with IL-1 in the presence of TGF-β in analogous 
fashion to IL-6. 36 In considering the role of IL-21 in RA, it 
is important to keep in mind that IL-21 is produced not only by 
Th 17 cells themselves, but also by other T cell subsets, such as T 
follicular-helper cells, and that IL-21 has important eff ects on B 
cells that are likely signifi cant in RA. 
 Further clarification of roles for IL-21 in human Th17 
development will provide a rationale for blockade of IL-21 or 
the IL-21 receptor in RA. Besides IL-21 itself or the IL-21 receptor, 
downstream molecules of the IL-21 signaling cascade, such as 
Jak3, might represent an eff ective target in suppressing human 
Th 17 diff erentiation. CP-690,550 is an orally active Jak inhibitor 
that was initially developed as a “selective Jak3 inhibitor” for 
treatment of organ allograft  rejection, 53 but has now turned out 
to be a pan-Jak inhibitor. A randomized controlled trial of 264 
patients with active RA showed that all tested doses of CP-690,550 
were superior to placebo in ACR 20-response rate (70%–81% vs. 
29%) by week 6 as well as ACR 50 and 70 responses by week 4. 54 
Th erapeutic effi  cacy was noted as early as week 1. Th e incidence 
of infection in the treatment group was around 30% as compared 
to 26% in placebo group, none of which were attributed to 
opportunistic organisms or resulted in death. 54 
 IL-23 
 In mice, IL-23 is dispensable for Th17 differentiation, but 
important for proliferation and maturation of the Th 17 lineage. 10,55 
Th e IL-23 receptor is induced in a Stat3- 26 and RORγt-dependent 33 
fashion, but not in naïve CD4 T cells. 
 In humans, Volpe showed that lack of IL-23 did not completely 
abrogate, but substantially impaired Th 17 diff erentiation  in vitro. 37 
In the presence of TGF-β, IL-23 appears to synergize with IL-1 
in inducing the IL-23 receptor, ROR-c, and IL-17A/F. 36 Th is 
synergism with IL-1 is more robust than IL-6 or IL-21. 36 Given 
these data, IL-23 might play more important roles in human Th 17 
diff erentiation than in mice. Whereas no clinical study targeting 
IL-23 in RA has been reported yet, a phase II randomized clinical 
trial involving 320 patients with moderate-to-severe psoriasis 
showed that treatment with a monoclonal antibody against the 
IL-12/23 p40 subunit led to a dose-response improvement of 
the psoriasis area and severity index. 56 Th e incidence of serious 
adverse events was comparable between treatment and placebo 
group. However, in the treatment of RA, blockade of IL-23p19, 
an IL-23-specifi c component not shared with IL-12, would likely 
be more effi  cacious with less toxicity, in view of the regulatory 
eff ects of IL-12 on IL-17 production. 
 Besides IL-23 itself and its receptor, molecules downstream 
in the IL-23 signaling cascade, namely Jak2 or Tyk2, could be 
appealing targets for therapy. INCB028050 is a selective orally 
available Jak1/Jak2 inhibitor. Treatment with INCB028050 led to 
improvements in clinical, histologic, and radiographic aspects of 
rat adjuvant arthritis. 57 In this study, INCB028050 inhibited IL-6- 
and IL-23-mediated phosphorylation of Stat3 in a dose-dependent 
fashion along with selective inhibition of Jak1/Jak2. Expression of 
IFN-γ, IL-12, IL-17, IL-21, and IL-22 were suppressed by 50%–
80%. Taking all observations summarized above into account, 
we propose a model of human Th 17 diff erentiation as described 
in  Figure 1 . 
 What transcription factors drive human Th 17
diff erentiation? 
 Our knowledge as to what transcription factors drive human 
Th 17 cells is very limited. ROR-c was proven to be essential for 
IL-17 expression  in vitro. 36 T cells from patients with dominant 
negative mutations in Stat3 (autosomal-dominant hyper-
IgE syndrome: primary immunodefi ciency characterized by 
recurrent lung and skin infections, elevated serum IgE, pathologic 
fractures, characteristic face, and high palate) have impaired 
IL-17 production  ex vivo. 58 While these data suggest probable 
important involvement of these transcription factors in human 
Th 17 diff erentiation, there remain numerous open questions, such 
as i) what proinfl ammatory cytokines phosphorylate Stat3; ii) 
whether Stat3 induces ROR-c by binding to the ROR-c promoter; 
iii) whether Stat3 and ROR-c bind to the IL-17 promoter to induce 
IL-17 expression, and iv) which other transcription factors (Stat4, 
IRF4, Runx1 etc.) are involved in IL-17 expression. 
 No clinical studies targeting ROR-c have been conducted to 
date, which is not surprising given the relatively limited data as 
to how ROR-c is involved in human Th 17 development. 
 When it comes to Stat inhibition, one must block either their 
recruitment to cytokine receptors, dimerization, or DNA binding, 
since Stats do not have enzymatic activity. Over-expression of 
dominant negative alleles, mutants that cannot be phosphorylated, 
will not be very practical in the clinical setting in the near future. 
Instead, phosphopeptides corresponding either to motifs in 
cytokine receptors that prevent Stat recruitment or to conserved 
motifs in Stats themselves that prevent Stat dimerization might 
be a feasible strategy in disrupting Stat activation. 59–61 Decoy 
oligonucleotides may also deserve consideration given their 
potential for preventing Stat DNA binding. 62 
 A few lines of indirect evidence support the rationale for 
Stat3 inhibition in treating Th 17 driven autoimmune diseases, 
specifi cally RA. Socs3 is a negative feedback regulator of Stat3 that 
is induced by IL-6 and is abundantly expressed in synovial tissues 
in patients with RA. 63 Adenovirus carrying Socs3 cDNA was shown 
to be an eff ective tool in reducing phosphorylation of Stat3 and 
ameliorating CIA, and was more potent than a dominant negative 
form of Stat3. 63 CD4 T cells co-cultured with DCs transduced with 
Socs3, (which inhibit IL-23-mediated phosphorylation of Stat3 
and have high secretion of IL-10 but low IL-23p19 expression), 
produce less IL-17 than those co-cultured with nontransduced 
DCs. 64 Auranofi n: a sulphur-containing gold compound, which 
has previously been used in the treatment of RA, was shown to 
inhibit IL-6-mediated phosphorylation of Stat3 in fi broblast-like 
synoviocytes and impair its translocation to the nucleus. 65 
 In light of the probable contribution of Stat4 to Th17 
development in mice 35 as well as the observation that Stat4 defi cient 
mice were protected from CIA, 66 EAE, 67 and infl ammatory bowel 
disease, 68 Stat4 inhibition also might deserve consideration in 
treating Th 17 driven autoimmune diseases, including RA. 
 Several lines of evidence have shown that HMG-CoA 
reductase inhibitors, statins, ameliorated Th 17 driven autoimmune 
disease, partly through inhibition of Stat3 or Stat4. In patients with 
multiple sclerosis, simvastatin-induced Socs3, and suppressed 
Stat3 phosphorylation as well as IL-6 and IL-23 expression in 
monocytes. 69 In this study, simvastatin suppressed expression 
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of ROR-c and IL-17 in CD4 T cells cultured without antigen 
presenting cells. 69 Orally administered statins are eff ective in 
preventing and treating EAE 70 and CIA. 71 Statins inhibit Stat4 and 
enhance Stat6 phosphorylation, both in T cells from mice with 
EAE and  in vitro , associated with reduced production of IL-12 and 
IFN-γ, but increased secretion of IL-4 and IL-5. 70 Upon adoptive 
transfer, these Th 2 cells conferred resistance to EAE. 
 In a randomized controlled trial of 116 patients with RA 
treated with either 40mg of atorvastatin or placebo in conjunction 
with disease modifying therapy, treatment with atorvastatin 
was associated with signifi cant, albeit modest, improvement 
DAS28 as well as better DAS28-response rate (31%) than 
placebo(10%). 72 
 Can human Th 17 cells be redirected to other lineages as is the 
case in mice? 
 A growing body of evidence suggests that Th 17 cells represent 
a heterogeneous population of T cells with dynamic phenotypic 
and functional properties, both in mice and humans.  In vivo , 
IL-17(+)IFN-γ(+) cells and RORγt(+)FoxP3(+) cells 26,73 were 
identifi ed in both mice and humans.  In vitro , the combination 
of high TGF-β and IL-6 induces IL-17(+)IL-22(–) cells in mice 
and humans, 37,74 which may be either more or less pathogenic, 
depending on the specifi c diseases or aff ected organs. Whereas 
the combination of TGF-β and IL-6 induces IL-17(+)IL-10(+) 
cells, which are less pathogenic Th 17 cells in mice, restimulation 
of these cells by IL-23-induced IL-17(+)IL-10(–) cells, which are 
more pathogenic. 75 
 It was previously speculated that each subset of helper 
T lymphocytes represented a fi xed phenotype tightly linked 
to expression of a lineage-specific transcription factor in a 
mutually exclusive pattern. However, it is now clear that helper T 
lymphocytes can be redirected to other lineages in mice depending 
on the cytokine milieu. Th 1 and Th 2 cells, which have been viewed 
as relatively fi xed lineages, can be inter-converted to each other 
through exposure to IL-4 and IFN-γ, respectively. 76  In vitro -
generated Th 17 cells lose IL-17A and IL-17F expression without 
constant exposure to TGF-β and IL-6, and can be redirected to 
Th 1 cells through exposure to IFN-γ or IL-12. 77 Whether Th 17 
to Th 2 conversion can be induced by IL-4 is controversial. Our 
laboratory has shown that  in vitro -generated Th 17 cells lose IL-17 
expression when exposed to IL-4 in a Stat6-dependent fashion, 
but do not convert to Th 2 cells. Th 17 cells became resistant to 
regulation by IL-4 aft er 3 rounds (3 weeks) of restimulation 
in Th17 inducing conditions, associated with loss of Stat6 
phosphorylation but upregulation of Socs5 and Socs1 (L Cooney 
and D Fox, submitted), analogous to IL-27 inhibition of  de novo 
diff erentiation of Th 17 cells in a Stat1-dependent fashion, but 
inability of IL-27 to suppress already committed Th 17 cells. 78 In 
contrast, Lexberg found that  in vitro -generated Th 17 cells readily 
lost Th 17 phenotype and converted to Th 2 cells when exposed to 
IL-4, even aft er 18 days of polarization towards Th 17 cells while 
 in vivo -generated Th 17 cells maintained the Th 17 phenotype 
even under Th 1 or Th 2 inducing condition. 79 Th e discrepancies 
may be attributed to diff erences in the type of antigen presenting 
cells, protocol for Th 17 polarization, purity of Th 17 cells used for 
restimulation, and method of restimulation by IL-4. 
 In the setting of Treg-specifi c deletion of the RNaseIII enzyme 
Dicer that is required for microRNA biogenesis, Tregs can be 
reprogramed to Th 1 and Th 2 cells. 80 Tregs can be redirected to 
Th 17 30,81 and follicular helper T cells (Tfh ) 82 through exposure 
to IL-6 or IL-21 and interaction with B cells through CD40 
respectively. In humans, Tregs can be reprogramed to Th 17 cells 
through exposure to IL-1 and IL-6  in vitro. 73 
 Figure 1.  Model of human Th17 differentiation: IL-1 signaling appears to cooperate with a pathway driven by TGF-+ IL-6/IL-21/IL-23 to induce human Th17 cells, associated 
with expression of ROR-c and Stat3. IL-23 might promote differentiation of human Th17 cells to a pathogenic phenotype, which contribute to autoimmune pathology. Human 
Th17 cells, depending on the stage of development, might lose Th17 phenotype or be redirected to Th1 cells by IFN-/IL-27/IL-12, Th2 cells by IL-4, or Tregs by IL-2 . 
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 In light of such complex phenomena concerning the 
heterogeneity and plasticity of helper T cells, O’Shea proposed a 
more sophisticated model, that views helper T cells as expressing 
various ratios of master regulator genes (T-bet, Gata3, and 
RORγt), which could dynamically change during the course 
of diff erentiation and development depending on the cytokine 
milieu. 83 
 Besides master regulator genes, it would be paramount 
to consider Signal Transducer and Activator of Transcription 
proteins (STATs) in discussing the diff erentiation and plasticity of 
helper T cells. In mice, Th 17 diff erentiation is inhibited by Stat1 
phosphorylation by IFN-γ or IL-27, Stat4 phosphorylation by 
IL-12, Stat5 phosphorylation by IL-2, or Stat6 phosphorylation 
by IL-4, all of which, except for Stat6, were shown to directly bind 
to the IL-17 promoter. 8,35 , 84–86 
 An important question is whether human Th 17 cells can be 
regulated or redirected to other lineages through exposure to 
IFN-γ, IL-27, IL-12, IL-2, or IL-4. Th is question is related to the 
issues of whether immune tolerance can be restored by cytokines 
with opposing phenotypes aft er generation of pathogenic Th 17 
cells in human autoimmune diseases.  Ex vivo expanded human 
Th 17 cells have reduced IL-17, but increased IFN-γ expression 
aft er treatment with IL-12, correlated with decreased expression 
of RORγt, but increased expression of T-bet. 87 
 Our laboratory has shown that DCs genetically engineered 
to express IL-4 suppress IL-17 production from T cells and 
ameliorate CIA even in the presence of strong Th 17 inducing 
stimuli, such as IL23, in mice. 38,39 Whether similar phenomena will 
be observed in humans and with other cytokines; IFN-γ, IL-27, 
IL-12, and IL-2, including alteration of sensitivity to regulation 
depending on the stage of Th 17 development, would be an area 
for vigorous research. Such information would bear on whether 
DCs genetically engineered to express IFN-γ, IL-27, IL-12, IL-2, 
or IL-4 could be a potential therapeutic modality in RA. 
 What is the implication of IL-17(+) IFN-γ(+)cells in RA? 
 IL-17(+)IFN-γ(+)cells are identifi ed in several human autoimmune 
diseases, including RA. Whether these cells represent a distinct 
population or cells in the process of diff erentiation to Th 1 or 
Th 17 lineage remains unclear. Since the discovery of Th 17 cells, 
it has also been a matter of debate whether pathogenesis of RA 
is mainly driven by Th 1 cells, Th 17 cells, or both, and whether 
this depends on the stage of the disease. 
 In proteoglycan-induced arthritis (PGIA), although IFN-γ 
defi cient mice develop less severe arthritis with delayed onset, 
they eventually succumb to arthritis. 88 Although IL-17 defi ciency 
does not protect mice from PGIA, IFN-γ(–/–) or T-bet(–/–) mice 
developed more severe PGIA than IFN-γ/IL-17 or T-bet/IL-17 
double defi cient mice. 88 Th e data can be interpreted to imply that 
IL-17-mediated pathology is regulated by IFN-γ in PGIA. In CIA, 
lack of IFN-γ signaling leads to severe disease. 4,5 Neutralization 
of IFN-γ was benefi cial at an earlier stage of CIA, but aggravated 
the disease at a later stage. 89 Th ese data implicate the possibility 
that roles for Th 1 and Th 17 immunity in mouse model of arthritis 
vary depending on the stage of the disease. 
 Studies in other animal models of autoimmune diseases might 
provide important clues in dissecting the link between Th 1 and 
Th 17 immunity in the development of RA. Th 17 cells are able to 
induce colitis upon transfer into immunodefi cient mice, but many 
of them convert to Th 1 cells. 77 Diabetogenic BDC2.5 CD4 T cells 
polarized  in vitro to the Th 17 phenotype lose IL-17 expression 
and express IFN-γ aft er adoptive transfer into NOD-SCID mice, 
ultimately causing beta-cell destruction and diabetes. 90 Finally, 
data showing that Th 1 cells can be reprogramed to Th 17 cells 
in mice and humans is lacking. In light of these observations, 
it might be plausible to speculate that an earlier stage of RA is 
primarily driven by Th 17 cells, which gradually convert to IL-
17(+)IFN-γ(+) cells and are fi nally replaced by Th 1 cells during 
the progression of disease. If this were the case, the presence of IL-
17(+)IFN-γ(+)cells might indicate that the disease is in the stage 
of conversion from Th 17 to Th 1 driven disease. In this regard, it 
would be quite intriguing to know whether there is any consistent 
link between the ratio of IL-17(+)cells versus IL-17(+)IFN-γ(+) 
cells versus IFN-γ(+) cells in peripheral blood or synovial fl uid 
and clinical and radiologic stage of disease in patients with RA. 
Th is might defi ne a therapeutic window when IL-17 blockade 
will be benefi cial in treating RA. 
 Which phenotypic features defi ne the pathogenicity of human 
Th 17 cells? 
 Understanding the diverse array of phenotypes and functions of 
Th 17 cells, some of which may be more pathogenic and others 
more tolerogenic, it has been a matter of debate as to which subset 
of Th 17 cells drives human autoimmune diseases. Furthermore, IL-
17-mediated immunopathology appears to be regulated by IFN-γ 
in mouse models of arthritis as above. From these perspectives, 
it is not entirely clear whether IL-17 blockade itself would be 
benefi cial throughout all stages of RA. Regardless, there are some 
promising studies supporting the rationale for IL-17 blockade 
in both mice and humans. IL-17 receptor Fc fusion protein 
attenuated clinical, radiologic, and histologic manifestations of 
rat adjuvant arthritis in a dose-dependent fashion. 91 In a double 
bind randomized controlled trial of 77 patients, treatment with 
humanized anti-IL-17 monoclonal antibody (LY2439821) led to 
greater changes in DAS28 score as well as ACR 20, 50, and 70 
responses than placebo. 92 Th ere was no apparent dose-response 
relationship in treatment-related adverse events. 
 In mice, IL-22 is produced by Th 17 cells in an IL-23-dependent 
fashion, but not by Th 17 cells induced by TGF-β and IL-6 alone, 
implicating that IL-22 might be a marker of maturation of Th 17 
cells. 75 However, it is controversial whether IL-17(+)IL-22(+) 
cells are pathogenic or not. In fact, IL-22 defi cient mice are not 
protected from EAE. 93 IL-22 is protective in liver, 94 gut, 95 and 
myocardial infl ammation. 96 On the other hand, IL-22 induces 
keratosis in mouse models of psoriasis and plays a role in human 
psoriasis as well. 97 IL-22 may promote the breach of the blood–
brain barrier in T cell-mediated CNS autoimmunity. 98 In RA, IL-
22 induces proliferation of synovial fi broblasts through the IL-22 
receptor expressed on these cells. 99 In bleomycin-induced airway 
infl ammation in mice, IL-22 was tissue protective in the absence 
of IL-17, but became pathogenic in cooperation with IL-17. 100 
Based on these data, it might be plausible to speculate that whether 
IL-22 is pathogenic or tolerogenic is entirely context dependent. 
Therefore, before considering this molecule as a potential 
target of therapy, the role for IL-22 in Th 17 driven autoimmune 
disease needs to be rigorously determined depending on the type 
of disease, aff ected organs, and the presence of concomitant 
IL-17. 
 What factors drive the pathogenic features of Th 17 cells? 
 Given the lack of a convincing answer to the last question, this 
also remains an open question. Our hypothesis is that IL-23, 
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which appears to cooperate with IL-1 to induce human Th 17 cells 
in the context of low TGF-β, also plays a crucial role in conferring 
pathogenicity to human Th 17 cells. First, the IL-23 receptor 
is induced in a Stat3 26 as well as RORγt-dependent 33 fashion, 
but not in naïve CD4T cells in mice. Second, IL-21, which is 
produced by Th 17 cells and promotes Th 17 diff erentiation in 
an autocrine fashion, 26,33,34 requires IL-23 for its expression in 
mice. Th ird, only IL-23 receptor positive Th 17 cells migrated 
to the site of infl ammation in EAE, producing more IL-17A 
than IL-23 receptor negative cells. 55 Finally, a crucial role for 
IL-23 in CIA was suggested given development of severe CIA 
in mice defi cient for IL-12p35, but not in mice defi cient for IL-
12/23p40 or IL-23p19, implicating a pathogenic role of IL-23, 
but not IL-12. 7 
 One potential approach to determine the role of IL-23 in 
conferring pathogenicity to Th 17 cells in RA would be to analyze 
the ability of naïve CD4 T cells cultured in TGF-β + IL-1 + IL-6 + 
various concentrations of IL-23 to interact with and activate 
fi broblast-like synoviocytes  in vitro . If this approach defi nes a 
role for IL-23 in pathogenesis of RA, it would further support 
the rationale for use of a monoclonal antibody against IL-23p19 
or the IL-23 receptor, as discussed previously. 
 Conclusion 
 Although recent studies have implicated numerous novel 
therapeutic strategies in RA as targeting multiple distinct aspects 
of development and function of Th 17 cells ( Table 3 ), whether 
these new modalities are feasible options in the actual clinical 
setting relies on further research to answer many open questions 
concerning the diff erentiation, plasticity, and pathogenicity of 
human Th 17 cells. 
Drugs Conceptual Th17 target Molecular target Stage of drug development
Anakinra Differentiation IL-1 receptor Approved for RA
Tocilizumab Differentiation IL-6 receptor Approved for RA
Ustekinumab Differentiation and pathogenicity IL-23p40 Approved for severe plaque 
psoriasis
Statins Differentiation and pathogenicity Multiple Effi cacy proven in a RCT
Auranofi n Differentiation and pathogenicity Stat3 Previously used
CP-690,550 (pan-Jak inhibitor) Differentiation and pathogenicity IL-6, 21, 23 signaling Phase II trials suggest effi cacy
LY2439821 (Anti-IL17A monoclonal antibody) Pathogenicity IL-17A Phase I trial completed
IL-21 receptor Fc fi sion protein Differentiation IL-21 receptor Animal study
INCB028050 (Jak1/Jak2 inhibitor) Differentiation and pathogenicity IL-6, 23 signaling Animal study
Monoclonal Ab againt IL-23p19 Differentiation and pathogenicity IL-23p19 Not studied yet
ROR-c inhibitor Differentiation ROR-c Not studied yet
Stat3 inhibitor Differentiation and pathogenicity Stat3 Not studied yet
Stat4 inhibitor Differentiation and pathogenicity Stat4 Not studied yet
DCs expressing TGF-β Differentiation multiple Not studied yet
DCs expressing IFN-γ/IL-27/IL-12/IL-2/IL-4 Plasticity Stats? Not studied yet
IL-22 blockade Pathogenicity? IL-22 Awaits further studies
 Table 3. Novel therapeutic strategies in RA targeting multiple aspects of Th17 biology. 
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